Stefanini, B., Fulgenzi, C., Scheiner, B., Korolewicz, J., Cheon, J., Nishida, N., Ang, C., Marron, T., Wu, Y. L., Saeed, A., Wietharn, B., Rimassa, L., Pirozzi, A., Cammarota, A., Pressiani, T., Pinter, M., Balcar, L., Huang, Y.-H., Mehan, A., … D’Alessio, A. (2025). ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab. Journal of Hepatocellular Carcinoma, Volume 12, 671–683. https://doi.org/10.2147/jhc.s462701

Mendez, J. S., Cohen, A. L., Eckenstein, M., Jensen, R. L., Burt, L. M., Salzman, K. L., Chamberlain, M., Hsu, H. H., Hutchinson, M., Iwamoto, F., Ligon, K. L., Mrugala, M. M., Pelayo, M., Plotkin, S. R., Puduvalli, V. K., Raizer, J., Reardon, D. A., Sterba, M., Walbert, T., … Colman, H. (2024). Phase 1b/2 Study of Orally Administered Pexidartinib in Combination with Radiation Therapy and Temozolomide in Patients with Newly Diagnosed Glioblastoma. Neuro-Oncology Advances. https://doi.org/10.1093/noajnl/vdae202

Sommerhalder, D., Demel, K., Noel, M. S., Emamekhoo, H., Peguero, J., Balaraman, R., Moy, R. H., Scheuber, A., Haas, J., Chabas, D., Kumar, P., Daigle, S. R., Dasen, S., Zhang, X., Gutierrez, M., Sharma, S., & Hussain, A. (2024). 682 Ongoing phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: clinical safety update and renal cell carcinoma (RCC) efficacy analysis. Regular and Young Investigator Award Abstracts, A782–A783. https://doi.org/10.1136/jitc-2024-sitc2024.0682

Zhou, J. J., Chen, L. N., Lehan, T., Herzberg, B., Henick, B. S., Pitman, M., Gallitano, S., & Shu, C. A. (2024). Severe scalp ulcerations and granulomata during treatment with amivantamab. Current Problems in Cancer: Case Reports, 13, 100273. https://doi.org/10.1016/j.cpccr.2023.100273

Lee, J. M., Toloza, E. M., Pass, H. I., Johnson, B. E., Heymach, J. V., Sholl, L., Saqi, A., Travis, W. D., Wistuba, I., Lin, J., Kris, M. G., Spira, A. I., Shu, C. A., Saltos, A. N., Ding, B., Schulze, K., Zhu, Q., Ngiam, C., Bara, I., & Chaft, J. E. (2023). P2.01-06 NAUTIKA1 Study: Preliminary Efficacy and Safety Data with Neoadjuvant Alectinib in Patients with Stage IB-III ALK+ NSCLC. Journal of Thoracic Oncology, 18(11), S297–S298. https://doi.org/10.1016/j.jtho.2023.09.511

Basu, A., Umashankar, S., Musthafa, M., Jones, T., Blevins, K., Brown, T., Heditsian, D., Parker, B., Brain, S., Simmons, C., Hieken, T. J., Ruddy, K., Mainor, C., Tevis, S., Blaes, A., Rugo, H. S., Dunn, I., Melisko, M., Esserman, L., & Hershman, D. L. (2023). 374P Evaluation of symptom severity, tolerability, and physical function in the I-SPY2 trial. Annals of Oncology, 34, S332–S333. https://doi.org/10.1016/j.annonc.2023.09.552

Le, X., Patel, J., Shum, E., Sanborn, R. E., Baik, C. S., Shu, C. A., Kim, C., Fidler, M. D., Hall, R., Hanna, N., Mohindra, N., Sabari, J. K., Heeke, S., Hernandez, M., Gray, J. E., Heymach, J. V., & Saltos, A. (2023). LBA71 A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis). Annals of Oncology, 34, S1313–S1314. https://doi.org/10.1016/j.annonc.2023.10.072

LaRose, M., Zhou, M., Lu, S., Wei, H., Bates, S. E., Schwartz, L., & Fojo, A. T. (2023). 1328P Analysis of data from the AENEAS study assessing the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), aumolertinib, and virtual comparison with osimertinib. Annals of Oncology, 34, S766–S767. https://doi.org/10.1016/j.annonc.2023.09.2361

Senna, M., Forman, S., Bordone, L., De La Cueva Dobao, P., Wolk, R., Zwillich, S., Zhang, F., Mohamed Ahmed, H., & Takiya, L. (2023). Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study. SKIN The Journal of Cutaneous Medicine, 7(4), s224. https://doi.org/10.25251/skin.7.supp.224

Bullock, A., Fakih, M., Gordon, M., Tsimberidou, A., El-Khoueiry, A., Wilky, B., Pimentel, A., Margolin, K., Mahadevan, D., Balmanoukian, A., Sanborn, R., Schwartz, G., Abou-Alfa, G., Bockorny, B., Moser, J., Sharma, S., Grossman, J., Rosenthal, K., O’Day, S., … Schlechter, B. (2023). LBA-4 Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC). Annals of Oncology, 34, S178–S179. https://doi.org/10.1016/j.annonc.2023.04.014

Li, T., Kikuchi, O., Zhou, J., Wang, Y., Pokharel, B., Bastl, K., Gokhale, P., Knott, A., Zhang, Y., Doench, J. G., Ho, Z. V., Catenacci, D. V. T., & Bass, A. J. (2023). Developing SHP2-based combination therapy for KRAS-amplified cancer. JCI Insight, 8(3). https://doi.org/10.1172/jci.insight.152714

Loibl, S., Loirat, D., Tolaney, S. M., Punie, K., Oliveira, M., Rugo, H. S., Bardia, A., Hurvitz, S. A., Brufsky, A. M., Kalinsky, K., Cortés, J., O’Shaughnessy, J. A., Dieras, V., Carey, L. A., Gianni, L., Gharaibeh, M., Preger, L., Phan, S., Chang, L., … Piccart, M. J. (2023). Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. European Journal of Cancer, 178, 23–33. https://doi.org/10.1016/j.ejca.2022.10.003

Rugo, H. S., Tolaney, S. M., Loirat, D., Punie, K., Bardia, A., Hurvitz, S. A., O’Shaughnessy, J., Cortés, J., Diéras, V., Carey, L. A., Gianni, L., Piccart, M. J., Loibl, S., Goldenberg, D. M., Hong, Q., Olivo, M., Itri, L. M., & Kalinsky, K. (2022). Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. Npj Breast Cancer, 8(1). https://doi.org/10.1038/s41523-022-00467-1